阿哌沙班与依替巴肽在透析伴房颤患者中的应用：P2Y12 抑制剂抗凝方案对预后的影响。
Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation.
机构信息
Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
Nephrology Division, Department of Medicine, New York University Langone Medical Center, New York, New York.
出版信息
Kidney360. 2022 Aug 1;3(10):1769-1771. doi: 10.34067/KID.0003002022. eCollection 2022 Oct 27.
Abstract
In patients with atrial fibrillation on dialysis, the incidence of stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription.In patients with atrial fibrillation on dialysis who were on a P2Y12 inhibitor, apixaban increased the risk of bleeding, compared with no anticoagulation.The incidence of myocardial infarction or ischemic stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription status.
摘要
在接受透析治疗的房颤患者中，无论是否开具了 P2Y12 处方，阿哌沙班或不抗凝治疗的卒中发生率相似。在接受透析治疗且正在服用 P2Y12 抑制剂的房颤患者中，与不抗凝治疗相比，阿哌沙班增加了出血风险。无论 P2Y12 处方状态如何，阿哌沙班或不抗凝治疗的心肌梗死或缺血性卒中发生率相似。
相似文献
1
Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation.阿哌沙班与依替巴肽在透析伴房颤患者中的应用：P2Y12 抑制剂抗凝方案对预后的影响。
Kidney360. 2022 Aug 1;3(10):1769-1771. doi: 10.34067/KID.0003002022. eCollection 2022 Oct 27.
2
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.急性冠状动脉综合征或经皮冠状动脉介入治疗后早期和晚期心房颤动患者抗栓治疗的风险/获益权衡：来自 AUGUSTUS 的见解。
Circulation. 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29.
3
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.SAFE-A研究的原理与设计：阿哌沙班联合双重抗血小板治疗在接受经皮冠状动脉介入治疗的房颤患者中的安全性和有效性试验
J Cardiol. 2017 Apr;69(4):648-651. doi: 10.1016/j.jjcc.2016.06.007. Epub 2016 Jul 18.
4
Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.非瓣膜性心房颤动伴严重肾功能损害患者应用阿哌沙班的安全性结局。
J Thromb Thrombolysis. 2020 Aug;50(2):330-336. doi: 10.1007/s11239-019-02028-z.
5
Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis.利伐沙班与阿哌沙班用于终末期肾病或透析的非瓣膜性心房颤动患者。
Eur J Haematol. 2020 Apr;104(4):328-335. doi: 10.1111/ejh.13383. Epub 2020 Jan 29.
6
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.在阿哌沙班用于降低心房颤动患者中风和其他血栓栓塞事件试验中，心房颤动患者使用阿哌沙班与华法林的出血史及转归情况。
Am Heart J. 2016 May;175:175-83. doi: 10.1016/j.ahj.2016.01.005. Epub 2016 Jan 19.
7
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.在体重处于极端范围的房颤患者中，阿哌沙班与华法林的疗效和安全性。
Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
8
A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention.阿哌沙班治疗心房颤动、急性冠状动脉综合征和经皮冠状动脉介入治疗的药物安全性评价。
Expert Opin Drug Saf. 2019 Dec;18(12):1119-1125. doi: 10.1080/14740338.2019.1676723. Epub 2019 Oct 8.
9
Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.长期血液透析的心房颤动患者的口服抗凝治疗。
J Am Coll Cardiol. 2020 Jan 28;75(3):273-285. doi: 10.1016/j.jacc.2019.10.059.
10
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.服用阿哌沙班或华法林的房颤患者的大出血：ARISTOTLE 试验（阿哌沙班用于减少房颤中的中风和其他血栓栓塞事件）：预测因素、特征和临床结局。
J Am Coll Cardiol. 2014 May 27;63(20):2141-2147. doi: 10.1016/j.jacc.2014.02.549. Epub 2014 Mar 19.
引用本文的文献
1
Anticoagulation in Patients with Chronic Kidney Disease.慢性肾脏病患者的抗凝治疗。
Am J Nephrol. 2024;55(2):146-164. doi: 10.1159/000535546. Epub 2023 Nov 30.
本文引用的文献
1
Should Oral Anticoagulation Be Used in ESKD Patients on Hemodialysis with Atrial Fibrillation?: COMMENTARY.终末期肾病血液透析合并心房颤动患者是否应使用口服抗凝药？：评论
Kidney360. 2021 Apr 9;2(9):1412-1414. doi: 10.34067/KID.0001372021. eCollection 2021 Sep 30.
2
Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.行长期血液透析且新发心房颤动患者中应用阿哌沙班与不抗凝治疗的比较。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1146-1154. doi: 10.2215/CJN.11650919. Epub 2020 May 22.
3
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.心房颤动合并稳定性冠心病的抗栓治疗。
N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.
4
Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).抗血栓药物：从阿司匹林到 DOAC 在冠状动脉疾病和心房颤动中的应用（第 3/5 部分）。
J Am Coll Cardiol. 2019 Aug 6;74(5):699-711. doi: 10.1016/j.jacc.2019.02.080. Epub 2019 Jul 2.
Zotero 插件